Hsp110-mediated enhancement of CD4+ T cell responses to the envelope glycoprotein of members of the family Flaviviridae in vitro does not occur in vivo

Clinical and Vaccine Immunology

Volumn 18, Issue 2, 2011, Pages 311-317

  McLaughlin, Kerry ^a   Carr, Veronica B ^a   Iqbal, Munir ^a   Seago, Julian ^a   Lefevre, Eric A ^a   Robinson, Lucy ^a   Prentice, Helen ^a   Charleston, Bryan ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; GAMMA INTERFERON; GLYCOPROTEIN E2; INTERLEUKIN 10; NEUTRALIZING ANTIBODY; QUIL A; RECOMBINANT BOVINE HEAT SHOCK PROTEIN 110 GLYCOPROTEIN E2 COMPLEX; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOVINE DIARRHEA VIRUS; CATTLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; ENDOCYTOSIS; FLAVIVIRUS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPRECIPITATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CATTLE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DIARRHEA VIRUSES, BOVINE VIRAL; HSP110 HEAT-SHOCK PROTEINS; IMMUNOPRECIPITATION; MONOCYTES; PROTEIN BINDING; SAPONINS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 79551479871     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00414-10     Document Type: Article

References (42)

1. Anderton, S., R. van der Zee, B. Prakken, A. Noordzij, and W. van Eden. 1995. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. J. Exp. Med. 181:943-952.
2. Bendz, H., et al. 2007. Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J. Biol. Chem. 282:31688-31702.
3. Binder, R. J. 2006. Heat shock protein vaccines: from bench to bedside. Int. Rev. Immunol. 25:353-375.
4. Blachere, N. E., et al. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186:1315-1322.
5. Bogers, W. M. J. M., et al. 2004. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. AIDS 18:25-36.
6. Ciupitu, A.-M. T., et al. 1998. Immunization with a Lymphocytic Choriomeningitis Virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187:685-691.
7. Doody, A. D. H., et al. 2004. Glycoprotein 96 can chaperone both MHC Class I- and Class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J. Immunol. 172:6087-6092.
8. Gao, B., and M.-F. Tsan. 2003. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of Tumor Necrosis Factor alpha release by murine macrophages. J. Biol. Chem. 278:174-179.
9. Haug, M., et al. 2005. The heat shock protein Hsp70 enhances antigen-specific proliferation of human CD4+ memory T cells. Eur. J. Immunol. 35:3163-3172.
10. Hietala, S. K., and B. M. Crossley. 2005. Virus replication, p. 81-89. In S. M. Goyal and J. M. Ridpath (ed.), Bovine diarrhea virus: diagnosis, management and control. Wiley-Blackwell, Oxford, United Kingdom.
11. Insel, R. A. 1995. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann. N. Y. Acad. Sci. 754:35-48.
12. Kim, H. L., X. Sun, J. R. Subjeck, and X. Y. Wang. 2007. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol. Immunother. 56:1097-1105.
13. Koelle, D. M., et al. 2008. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects. Clin. Vaccine Immunol. 15:773-782.
14. Kumaraguru, U., M. Gierynska, S. Norman, B. D. Bruce, and B. T. Rouse. 2002. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J. Virol. 76:136-141.
15. Kwong, L. S., et al. 2002. Development of an ELISA for bovine IL-10. Vet. Immunol. Immunopathol. 85:213-223.
16. Lefevre, E. A., B. V. Carr, H. Prentice, and B. Charleston. 2009. A quantitative assessment of primary and secondary immune responses in cattle using a B cell ELISPOT assay. Vet. Res. 40:3.
17. Manjili, M. H., et al. 2002. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res. 62:1737-1742.
18. Manjili, M. H., et al. 2003. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J. Immunol. 171:4054-4061.
19. Manjili, M. H., et al. 2002. Immunotherapy of cancer using heat shock proteins. Front. Biosci. 7:d43-d52.
20. Martinez-Donato, G., et al. 2010. Ratio of HCV structural antigens in protein based vaccine formulations is critical for functional immune response induction. Biotechnol. Appl. Biochem. 56:111-118.
21. McLaughlin, K., J. Seago, L. Robinson, C. Kelly, and B. Charleston. 2010. Hsp70 enhances presentation of FMDV antigen to bovine CD4+ T cells in vitro. Vet. Res. 41:36.
22. Oh, H. J., X. Chen, and J. R. Subjeck. 1997. Hsp110 protects heat-denatured proteins and confers cellular thermoresistance. J. Biol. Chem. 272:31636-31640.
23. Pack, C. D., U. Kumaraguru, S. Suvas, and B. T. Rouse. 2005. Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with Herpes Simplex Virus. Vaccine 23:3526-3534.
24. Peng, M., et al. 2006. Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70. Vaccine 24:887-896.
25. Pockley, A. G. 2003. Heat shock proteins as regulators of the immune response. Lancet 362:469-476.
26. SenGupta, D., et al. 2004. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J. Immunol. 173:1987-1993.
27. Shortman, K., M. H. Lahoud, and I. Caminschi. 2009. Improving vaccines by targeting antigens to dendritic cells. Exp. Mol. Med. 41:61-66.
28. Srivastava, P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20:395-425.
29. Srivastava, P. K. 2006. Therapeutic cancer vaccines. Curr. Opin. Immunol. 18:201-205.
30. Su, C., et al. 2007. Heterologous expression of FMDV immunodominant epitopes and HSP70 in P. pastoris and the subsequent immune response in mice. Vet. Microbiol. 124:256-263.
31. Tobian, A. A., D. H. Canaday, W. H. Boom, and C. V. Harding. 2004. Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages. J. Immunol. 172:5277-5286.
32. Tobian, A. A., D. H. Canaday, and C. V. Harding. 2004. Bacterial heat shock proteins enhance class II MHC antigen processing and presentation of chaperoned peptides to CD4+ T cells. J. Immunol. 173:5130-5137.
33. Vaughn, J. L., R. H. Goodwin, G. J. Tompkins, and P. McCawley. 1977. The establishment of two cell lines from the insect Spodoptera frugiperda (Lepidoptera; Noctuidae). In Vitro 13:213-217.
34. Wang, R., J. T. Kovalchin, P. Muhlenkamp, and R. Y. Chandawarkar. 2006. Exogenous heat shock protein 70 binds macrophage lipid raft microdomain and stimulates phagocytosis, processing, and MHC-II presentation of antigens. Blood 107:1636-1642.
35. Wang, X.-Y., et al. 2004. Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods 32:13-20.
36. Wang, X.-Y., et al. 2010. Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen. J. Immunol. 184:6309-6319.
37. Wang, X. Y., et al. 2003. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res. 63:2553-2560.
38. Webster, D. P., J. Farrar, and S. Rowland-Jones. 2009. Progress towards a dengue vaccine. Lancet Infect. Dis. 9:678-687.
39. Wendling, U., et al. 2000. A conserved mycobacterial heat shock protein (hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian selfhsp70 homologue. J. Immunol. 164:2711-2717.
40. Wood, C., et al. 2008. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372:145-154.
41. Ye, Z., and Y.-H. Gan. 2007. Flagellin contamination of recombinant heat shock protein 70 is responsible for its activity on T cells. J. Biol. Chem. 282:4479-4484.
42. Zhao, Y., D. A. G. Chapman, and I. M. Jones. 2003. Improving baculovirus recombination. Nucleic Acids Res. 31:e6.